In the Phase 3 AFFIRM study, SKYRIZI (risankizumab) achieved superiority in co-primary endpoints of clinical remission and endoscopic response at week 12 for subcutaneous induction in patients with Crohn’s disease.
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has officially closed its acquisition of San Diego-based Avidity Biosciences, marking one of the most significant deals in the neuromuscular disease space in recent years. The transaction, originally announced on October 26, 2025, values Avidity at approximately $12 billion on a fully diluted basis, with an enterprise value of roughly $11 billion.
The FDA has approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as the first perioperative treatment regimen to significantly improve survival in cisplatin-ineligible patients with muscle-invasive bladder cancer. Based on pivotal Phase 3 EV-303 trial data, the combination demonstrated a 60% reduction in recurrence or death risk and a 50% reduction in mortality risk compared to surgery alone.
Eli Lilly and Company has announced breakthrough results from ACHIEVE-3, a head-to-head clinical trial that establishes orforglipron as a superior oral GLP-1 receptor agonist for type 2 diabetes management. The investigational medication outperformed oral semaglutide across all primary and key secondary endpoints, delivering clinically meaningful improvements in blood sugar control and weight loss. With FDA obesity approval expected in Q2 2026 and regulatory submissions already filed in over 40 countries, orforglipron represents a significant advancement in cardiometabolic treatment options.
IQVIA Holdings Inc. announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. The acquisition includes five sites specializing in in vitro drug discovery services, supported by over 20 years of scientific data, creating an industry-leading integrated drug discovery platform.
Pfizer announced FDA full approval of BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for treating adults with BRAF V600E-mutant metastatic colorectal cancer. The landmark approval is backed by Phase 3 BREAKWATER trial data demonstrating a 51% reduction in mortality risk and 47% reduction in disease progression risk compared to standard chemotherapy.
Novo Nordisk announced today a significant reduction in US list prices for
Wegovy, Ozempic, and Rybelsus, with prices dropping to $675 per month effective
January 1, 2027. The price cuts approximately 50% for Wegovy and 35% for Ozempic
represent a major step toward improving patient access and affordability for
obesity and type 2 diabetes treatments.
Eli Lilly expands Zepbound access with FDA-approved KwikPen multi-dose device. Patients can now choose between KwikPen or single-dose vials at the same price through LillyDirect, with self-pay pricing offering 50% or greater discount compared to other GLP-1 medicines.
Johnson & Johnson announces groundbreaking long-term clinical data revealing that TREMFYA (guselkumab) maintains sustained clinical, endoscopic, and histologic remission in adults with moderately to severely active ulcerative colitis through 3 years of treatment. The QUASAR long-term extension study demonstrates 80.8% clinical remission and 78.6% mucosal healing rates, setting new standards for inflammatory bowel disease management.
On February 20, 2026, the U.S. FDA approved the combination of Venclexta (venetoclax) and acalabrutinib for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This landmark decision establishes the first and only all-oral, fixed-duration (time-limited) regimen for previously untreated patients, offering a significant alternative to continuous therapy or chemoimmunotherapy
